Want to see FR:ALDVI full AI Analyst Report?
ALDVI Stock Chart & Stats
€1.72
€0.01(0.70%)
At close: 4:00 PM EST
€1.72
€0.01(0.70%)
Day’s Range― - ―
52-Week Range€0.80 - €2.35
Previous CloseN/A
Volume979.00
Average Volume (3M)26.23K
Market Cap
€32.17M
Enterprise Value€33.89M
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume23,481
30 Day Avg. Volume26,231
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€7.20M
Bulls Say, Bears Say
Bulls Say
Orphan Specialty FocusAdvicenne's focus on rare renal diseases and a proprietary prolonged‑release formulation (Sibnayal®) creates a structurally defensible niche. Chronic, specialty treatment dynamics and targeted prescriber channels support durable demand and pricing power versus mass-market competition.
Commercial Product Revenue ModelA prescription sales model tied to an approved specialty drug provides recurring, utilization‑based revenue potential when patient diagnosis and long‑term treatment persist. Licensing and partnership optionality can supply non‑dilutive milestones and geographic expansion paths over time.
Improving Gross ProfitabilityTransitioning to positive gross margins indicates improving unit economics from pricing, manufacturing, or mix improvements. If sustained, this creates a foundation for operating leverage as commercial scale grows, improving prospects for moving toward sustainable profitability.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external financing to sustain operations and commercialization. Over a multi‑month horizon this raises refinancing and dilution risk, constrains reinvestment in sales/marketing, and limits runway for strategic initiatives.
Negative Equity / Stressed Balance SheetNegative equity across multiple years signals a structurally weakened balance sheet that limits borrowing capacity and heightens insolvency risk. This fragile capital structure reduces strategic flexibility and increases vulnerability to reimbursement, regulatory, or commercial setbacks.
Volatile And Declining RevenuesIrregular and recently declining revenues undermine ability to achieve steady scale and predictable margins. For a specialty drug reliant on steady patient uptake and reimbursement, this volatility complicates forecasting, investment planning, and achievement of sustainable operating leverage.
Advicenne SA News
ALDVI FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.80 and its highest was €2.35 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €32.17M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Sep 17, 2026 which is in 70 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Mar 26, 2026. The company reported -€0.314 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.314.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of -€0.314 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.933%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in FR:ALDVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.